TUBITAK Marmara Research Center, Kocaeli 41470, Türkiye.
Department of Biotechnology, Institute of Biotechnology, Gebze Technical University, Kocaeli 41400, Türkiye.
Int J Mol Sci. 2023 Jul 26;24(15):11957. doi: 10.3390/ijms241511957.
C-Vx is a bioprotective product designed to boost the immune system. This study aimed to determine the antiviral activity of the C-Vx substance against SARS-CoV-2 infection. The effect of C-Vx in K18-hACE2 transgenic mice against the SARS-CoV-2 virus was investigated. For this purpose, ten mice were separated into experimental and control groups. Animals were infected with SARS-CoV-2 prior to the administration of the product to determine whether the product has a therapeutic effect similar to that demonstrated in previous human studies, at a histopathological and molecular level. C-Vx-treated mice survived the challenge, whereas the control mice became ill and/or died. The cytokine-chemokine panel with blood samples taken during the critical days of the disease revealed detailed immune responses. Our findings showed that C-Vx presented 90% protection against the SARS-CoV-2 virus-infected mice. The challenge results and cytokine responses of K18-hACE2 transgenic mice matched previous scientific studies, demonstrating the C-Vx's antiviral efficiency.
C-Vx 是一种旨在增强免疫系统的生物保护产品。本研究旨在确定 C-Vx 物质对 SARS-CoV-2 感染的抗病毒活性。研究了 C-Vx 在 K18-hACE2 转基因小鼠中对 SARS-CoV-2 病毒的作用。为此，将十只小鼠分为实验组和对照组。在给予产品之前，用 SARS-CoV-2 感染动物，以确定产品是否具有与之前在人类研究中证明的相似的治疗效果，在组织病理学和分子水平上。用 C-Vx 处理的小鼠经受住了挑战，而对照组的小鼠则患病和/或死亡。在疾病的关键几天采集的血液样本中的细胞因子-趋化因子谱揭示了详细的免疫反应。我们的研究结果表明，C-Vx 对感染 SARS-CoV-2 病毒的小鼠提供了 90%的保护。K18-hACE2 转基因小鼠的挑战结果和细胞因子反应与先前的科学研究一致，证明了 C-Vx 的抗病毒效率。
